Sical Logistics Eyes ₹92.8 Crore via Rights Issue

TRANSPORTATION
Whalesbook Logo
AuthorAbhay Singh|Published at:
Sical Logistics Eyes ₹92.8 Crore via Rights Issue
Overview

Sical Logistics Limited's Board of Directors has approved a rights issue to raise approximately ₹92.8 crore. The company will issue fully paid-up equity shares at ₹64 each, including a premium of ₹54. Eligible shareholders will receive 2 new shares for every 9 held as of the record date, February 18, 2026. The issue opens on February 26 and closes on March 10, 2026.

📉 The Financial Deep Dive

Sical Logistics Limited is set to raise approximately ₹92.8 crore through a rights issue, as approved by its Board of Directors on February 12, 2026. The company plans to issue equity shares at a price of ₹64 per share, which includes a face value of ₹10 and a premium of ₹54. This corporate action is designed to infuse fresh capital into the company, though the specific utilization of these funds has not been detailed in the announcement.

🚀 Strategic Analysis & Impact

The rights issue offers eligible shareholders the opportunity to acquire 2 new equity shares for every 9 shares held as of the record date, February 18, 2026. This mechanism allows existing shareholders to maintain their proportionate ownership in the company if they choose to subscribe. The issue price of ₹64 per share, compared to the current market price which has recently hovered around ₹90-₹92, suggests a potential discount that might incentivize subscription, while also indicating significant dilution for those who do not participate. The total capital raised, capped at ₹92.8 crore, signifies a substantial move for Sical Logistics, aimed at strengthening its financial base or funding future growth initiatives. Previous reports indicated a ₹110 crore rights issue approved earlier in January 2026, suggesting a revision or refinement of the fundraising plan.

🚩 Risks & Outlook

The primary risk for retail investors lies in the dilution of their equity stake if they do not subscribe to the rights issue. The company's financial health, as indicated by recent reports showing a poor sales growth of -26.1% over the past five years and a highly leveraged balance sheet with a negative ROE of -396%, suggests that capital infusion is critical. Investors must carefully consider the terms of the rights issue, their own financial capacity, and the company's future prospects before deciding to subscribe, sell, or let their rights lapse. The company's ability to effectively utilize the raised capital to improve its financial performance and operational efficiency will be key to determining the long-term impact on shareholder value.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.